Infant Bacterial Therapeutics AB (publ) (ST:IBT-B) — Stock Price
Infant Bacterial Therapeutics AB (publ) (ST:IBT-B) is currently trading at Skr68.10 SEK, up 2.71% today. Over the past 52 weeks, shares have ranged between Skr43.45 and Skr71.20. This page tracks Infant Bacterial Therapeutics AB (publ)'s live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Infant Bacterial Therapeutics AB (publ) worth.
Infant Bacterial Therapeutics AB (publ) (IBT-B) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Infant Bacterial Therapeutics AB (publ)'s daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.
Infant Bacterial Therapeutics AB (publ) Income Statement — Revenue, Profit & Earnings by Year
Infant Bacterial Therapeutics AB (publ)'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | Skr4.00K | Skr77.00K | Skr12.00K | Skr0.00 | Skr0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | Skr4.00K | Skr77.00K | Skr12.00K | — | — |
| Research & Development | Skr120.61 Million | Skr121.18 Million | Skr65.82 Million | Skr44.67 Million | Skr72.23 Million |
| SG&A | Skr19.30 Million | Skr13.51 Million | — | — | — |
| Total Operating Expenses | Skr139.90 Million | Skr134.69 Million | Skr65.81 Million | Skr44.58 Million | Skr71.92 Million |
| Operating Income | Skr-139.90 Million | Skr-134.62 Million | Skr-65.81 Million | Skr-44.58 Million | Skr-71.92 Million |
| EBITDA | Skr-136.91 Million | Skr11.55 Million | Skr-64.34 Million | Skr-43.76 Million | Skr-70.89 Million |
| EBIT | Skr-282.25 Million | Skr-123.07 Million | Skr-65.16 Million | Skr-44.58 Million | Skr-71.70 Million |
| Interest Expense | Skr0.00 | Skr9.00K | Skr293.00K | Skr413.00K | Skr303.00K |
| Income Before Tax | Skr-136.91 Million | Skr-123.07 Million | Skr-65.45 Million | Skr-44.99 Million | Skr-72.01 Million |
| Income Tax Expense | — | Skr-134.62 Million | Skr-357.00K | Skr413.00K | Skr303.00K |
| Net Income | Skr-136.91 Million | Skr-123.07 Million | Skr-65.45 Million | Skr-44.99 Million | Skr-72.31 Million |
Infant Bacterial Therapeutics AB (publ) Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Infant Bacterial Therapeutics AB (publ)'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | Skr239.57 Million | Skr351.33 Million | Skr349.62 Million | Skr408.48 Million | Skr450.32 Million |
| Total Current Assets | Skr230.61 Million | Skr341.56 Million | Skr339.03 Million | Skr397.09 Million | Skr438.12 Million |
| Cash & Equivalents | Skr223.39 Million | Skr329.06 Million | Skr335.84 Million | Skr386.75 Million | Skr423.44 Million |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Skr4.77 Million | Skr6.74 Million | Skr1.78 Million | Skr1.20 Million | Skr491.00K |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Skr69.30 Million | Skr46.18 Million | Skr17.91 Million | Skr13.22 Million | Skr10.16 Million |
| Total Current Liabilities | Skr69.30 Million | Skr46.18 Million | Skr17.91 Million | Skr13.22 Million | Skr10.16 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | Skr-223.39 Million | Skr-329.06 Million | Skr-335.84 Million | Skr-386.75 Million | Skr-423.44 Million |
| Total Stockholder Equity | Skr170.26 Million | Skr305.15 Million | Skr331.71 Million | Skr395.25 Million | Skr440.15 Million |
| Retained Earnings | Skr-602.25 Million | Skr-465.35 Million | Skr-342.28 Million | Skr-276.83 Million | Skr-231.84 Million |
Infant Bacterial Therapeutics AB (publ) Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Infant Bacterial Therapeutics AB (publ) generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | Skr-113.13 Million | Skr-101.22 Million | Skr-85.80 Million | Skr-55.62 Million | Skr-58.39 Million |
| Capital Expenditures | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 |
| Free Cash Flow | Skr-113.13 Million | Skr-101.22 Million | Skr-85.80 Million | Skr-55.62 Million | Skr-58.39 Million |
| Investing Cash Flow | — | Skr-4.15 Million | Skr-1.00K | — | — |
| Financing Cash Flow | Skr2.01 Million | Skr96.52 Million | Skr1.88 Million | Skr91.00K | Skr1.76 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Skr816.00K | Skr816.00K | Skr816.00K | Skr816.00K | Skr816.00K |
| Change in Cash | Skr-105.68 Million | Skr-6.78 Million | Skr-50.91 Million | Skr-36.69 Million | Skr-71.75 Million |
Infant Bacterial Therapeutics AB (publ) Earnings History — EPS Actual vs. Analyst Estimates
Track Infant Bacterial Therapeutics AB (publ)'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 05, 2026 | — | — | — |
| Feb 06, 2026 | — | — | — |
| Nov 13, 2025 | -0.75 | — | — |
| Aug 20, 2025 | -1.42 | — | — |
| May 07, 2025 | -1.24 | — | — |
| Feb 13, 2025 | -2.51 | — | — |
| Nov 14, 2024 | -2.42 | — | — |
| Aug 28, 2024 | -3.17 | — | — |